Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRelx Regulatory News (REL)

Share Price Information for Relx (REL)

Share Price is delayed by 15 minutes
Get Live Data
2,616.00    33.00 (1.28%)
Bid:
2,608.00
Ask:
2,610.00
Spread: 2.00 (0.077%)
Market Cap: £46.09b
REL Live PriceLast checked at - London Stock Exchange

Intraday Relx Share Chart

Annual Financial Report

19 Feb 2026 11:54

RNS Number : 7063T
RELX PLC
19 February 2026
 

19 February 2026 

RELX PLC

Publication of 2025 Annual Report and Annual Report on Form 20-F

 

RELX PLC (the "Company") has today published the following documents on its website at www.relx.com:

 

- Annual Report for the year ended 31 December 2025 (the "2025 Annual Report");

 

- Annual Report on Form 20-F for the year ended 31 December 2025 (the "2025 Form 20-F");

 

- 2025 Annual Report with Netherlands specific audit opinion (the "2025 NL Annual Report"); and

 

The 2025 Annual Report will be submitted to the National Storage Mechanism today and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

The 2025 Form 20-F will be filed with the US Securities and Exchange Commission ("SEC") today and will be available on the SEC's website at www.sec.gov. Hard copies of the Form 20-F, including the Company's audited financial statements, are available to any holders of RELX's securities free of charge upon request. Requests should be directed to RELX PLC, Company Secretariat, 1-3 Strand, London WC2N 5JR or to company.secretariat@relx.com.

 

The 2025 NL Annual Report has been published in accordance with the European Single Electronic Format requirements as in force in the European Union and applicable to RELX by virtue of its listing on Euronext Amsterdam and will be submitted to the Dutch Authority for the Financial Markets ("AFM"). The AFM publishes the report in its public register.

 

The total number of voting rights in RELX PLC's issued share capital (exclusive of shares held in treasury) is currently 1,812,039,253.

 

Forward-looking statements

The 2025 Annual Report and the 2025 Form 20-F contain forward-looking statements within the meaning of Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results or outcomes of RELX PLC (together with its subsidiaries, "RELX", "we" or "our") to differ materially from those expressed in any forward-looking statement. We consider any statements that are not historical facts to be "forward-looking statements". The terms "outlook", "estimate", "forecast", "project", "plan", "intend", "expect", "should", "could", "will", "believe", "trends" and similar expressions may indicate a forward-looking statement. Important factors that could cause actual results or outcomes to differ materially from estimates or forecasts contained in the forward-looking statements include, among others: regulatory and other changes regarding the collection or use of personal data; changes in law and legal interpretation affecting our intellectual property rights and internet communications; current and future geopolitical, economic and market conditions; research integrity issues or changes in the payment model for our scientific, technical and medical research products; competitive factors in the industries in which we operate and demand for our products and services; our inability to realise the future anticipated benefits of acquisitions; compromises of our cybersecurity systems or other unauthorised access to our databases; changes in economic cycles, trading relations, communicable disease epidemics or pandemics, severe weather events, natural disasters and terrorism; failure of third parties to whom we have outsourced business activities; significant failure or interruption of our systems; our inability to retain high-quality employees and management; changes in tax laws and uncertainty in their application; exchange rate fluctuations; adverse market conditions or downgrades to the credit ratings of our debt; changes in the market values of defined benefit pension scheme assets and in the market related assumptions used to value scheme liabilities; breaches of generally accepted ethical business standards or applicable laws; and other risks referenced from time to time in the filings of RELX PLC with the US Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of the 2025 Annual Report and the 2025 Form 20-F. Except as may be required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of the 2025 Annual Report and the 2025 Form 20-F or to reflect the occurrence of unanticipated events.

 

- ENDS -

Enquiries

Paul Abrahams (Media)Tel: +44 20 7166 5724

paul.abrahams@relx.com

 

Paul Sullivan (Investors)

Tel: +44 20 7166 5751

paul.sullivan@relx.com

 

Notes for Editors

 

About RELX

RELX is a global provider of information-based analytics and decision tools for professional and business customers. RELX serves customers in more than 180 countries and territories and has offices in about 40 countries. It employs more than 37,000 people, around 40% of whom are in North America.

 

The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York stock exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £40bn/€46bn/$55bn.

 

*Note: Current market capitalisation can be found at http://www.relx.com/investorcentre

 

 

RELX PLC

1-3 Strand

London WC2N 5JR

United Kingdom

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSUKVARNRUUAAR
Date   Source Headline
1st Jun 202612:36 pmRNSTotal Voting Rights
1st Jun 202611:22 amRNSTransaction in Own Shares
1st Jun 202611:00 amRNS2025 Final Dividend Euro Equivalent
26th May 20264:27 pmRNSTransaction in Own Shares
26th May 20267:00 amRNSNon-Discretionary Share Buyback Programme
19th May 20263:03 pmRNSAdditional Listing
18th May 202611:43 amRNSTransaction in Own Shares
11th May 202612:54 pmRNSTransaction in Own Shares
5th May 20262:27 pmRNSTransaction in Own Shares
1st May 20262:25 pmRNSTotal Voting Rights
27th Apr 20262:48 pmRNSDirector/PDMR Shareholding
27th Apr 20262:23 pmRNSTransaction in Own Shares
27th Apr 202611:31 amRNSAdditional Listing
23rd Apr 20261:52 pmRNSResult of AGM
20th Apr 20262:06 pmRNSTransaction in Own Shares
13th Apr 202611:18 amRNSTransaction in Own Shares
7th Apr 202612:52 pmRNSTransaction in Own Shares
1st Apr 20263:14 pmRNSTotal Voting Rights
30th Mar 20264:20 pmRNSTransaction in Own Shares
26th Mar 20261:59 pmRNSAdditional Listing
23rd Mar 202610:02 amRNSNon-Discretionary Share Buyback Programme
20th Mar 20265:06 pmRNSTransaction in Own Shares
19th Mar 20265:10 pmRNSTransaction in Own Shares
18th Mar 20264:58 pmRNSTransaction in Own Shares
17th Mar 20265:11 pmRNSTransaction in Own Shares
16th Mar 20265:17 pmRNSTransaction in Own Shares
13th Mar 20265:35 pmRNSTransaction in Own Shares
12th Mar 20265:48 pmRNSTransaction in Own Shares
11th Mar 20264:57 pmRNSTransaction in Own Shares
11th Mar 20264:57 pmRNSTransaction in Own Shares
10th Mar 20265:03 pmRNSTransaction in Own Shares
9th Mar 20265:16 pmRNSTransaction in Own Shares
6th Mar 20265:37 pmRNSTransaction in Own Shares
6th Mar 202611:40 amRNSNotice of AGM
5th Mar 20265:46 pmRNSTransaction in Own Shares
4th Mar 20265:03 pmRNSTransaction in Own Shares
3rd Mar 20265:00 pmRNSTransaction in Own Shares
2nd Mar 20265:00 pmRNSTransaction in Own Shares
2nd Mar 20262:55 pmRNSTotal Voting Rights
27th Feb 20265:24 pmRNSTransaction in Own Shares
26th Feb 20265:36 pmRNSTransaction in Own Shares
25th Feb 20265:04 pmRNSTransaction in Own Shares
25th Feb 202612:28 pmRNSAdditional Listing
24th Feb 20264:58 pmRNSTransaction in Own Shares
23rd Feb 20265:11 pmRNSTransaction in Own Shares
20th Feb 20264:58 pmRNSTransaction in Own Shares
19th Feb 202611:54 amRNSAnnual Financial Report
17th Feb 20265:13 pmRNSTransaction in Own Shares
17th Feb 20267:30 amRNSDirector/PDMR Shareholding
13th Feb 20265:07 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.